[go: up one dir, main page]

HN2002000028A - Pirimidinas inhibidoras de metaloproteinasas - Google Patents

Pirimidinas inhibidoras de metaloproteinasas

Info

Publication number
HN2002000028A
HN2002000028A HN2002000028A HN2002000028A HN2002000028A HN 2002000028 A HN2002000028 A HN 2002000028A HN 2002000028 A HN2002000028 A HN 2002000028A HN 2002000028 A HN2002000028 A HN 2002000028A HN 2002000028 A HN2002000028 A HN 2002000028A
Authority
HN
Honduras
Prior art keywords
metaloproteinash
pyrimidins
inhibiting
mmp
themselves
Prior art date
Application number
HN2002000028A
Other languages
English (en)
Inventor
Barvian Nicole Chantel
Connor David Thomas
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HN2002000028A publication Critical patent/HN2002000028A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

SON INHIBIDORES SELECTIVOS DE MMP-13 LOS DERIVADOS DE PIRIMIDINA DE FORMULA.... O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS
HN2002000028A 2001-02-14 2002-02-11 Pirimidinas inhibidoras de metaloproteinasas HN2002000028A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26878101P 2001-02-14 2001-02-14

Publications (1)

Publication Number Publication Date
HN2002000028A true HN2002000028A (es) 2002-04-22

Family

ID=23024446

Family Applications (2)

Application Number Title Priority Date Filing Date
HN2002000028A HN2002000028A (es) 2001-02-14 2002-02-11 Pirimidinas inhibidoras de metaloproteinasas
HN2002000025A HN2002000025A (es) 2001-02-14 2002-02-11 Inhibidores de piridina de metaloproteinasas de la matriz

Family Applications After (1)

Application Number Title Priority Date Filing Date
HN2002000025A HN2002000025A (es) 2001-02-14 2002-02-11 Inhibidores de piridina de metaloproteinasas de la matriz

Country Status (36)

Country Link
US (2) US6881743B2 (es)
EP (1) EP1362033B1 (es)
JP (1) JP4249981B2 (es)
KR (1) KR20030075196A (es)
CN (1) CN1537101A (es)
AP (1) AP2003002840A0 (es)
AR (1) AR035936A1 (es)
AT (1) ATE358667T1 (es)
BG (1) BG108089A (es)
BR (1) BR0207863A (es)
CA (1) CA2434982A1 (es)
CR (1) CR7048A (es)
CZ (1) CZ20032143A3 (es)
DE (1) DE60219286T2 (es)
DO (1) DOP2002000332A (es)
EA (1) EA200300763A1 (es)
EC (1) ECSP034691A (es)
EE (1) EE200300391A (es)
ES (1) ES2283540T3 (es)
GT (1) GT200200014A (es)
HN (2) HN2002000028A (es)
HU (1) HUP0303152A2 (es)
IL (1) IL156912A0 (es)
IS (1) IS6871A (es)
MA (1) MA26989A1 (es)
MX (1) MXPA03006204A (es)
NO (1) NO20033570D0 (es)
OA (1) OA12544A (es)
PA (1) PA8538201A1 (es)
PE (1) PE20020995A1 (es)
PL (1) PL365098A1 (es)
SK (1) SK10022003A3 (es)
TN (1) TNSN02012A1 (es)
UY (1) UY27167A1 (es)
WO (1) WO2002064568A1 (es)
ZA (1) ZA200306041B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
WO2002064571A1 (en) 2001-02-14 2002-08-22 Warner-Lambert Company Llc Pyrimidine matrix metalloproteinase inhibitors
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
MXPA04002537A (es) 2001-10-12 2004-05-31 Warner Lambert Co Alquinos como inhibidores de metaloproteinasa de matriz.
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6933298B2 (en) 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
DE10160357A1 (de) * 2001-12-08 2003-06-18 Aventis Pharma Gmbh Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
CA2492391A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
BR0312727A (pt) * 2002-07-17 2005-04-19 Warner Lambert Co Combinação de um inibidor alostérico da metaloproteinase-13 de matriz com celecoxib ou valdecoxib
CA2495432A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
JP2006502114A (ja) * 2002-07-17 2006-01-19 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリクスメタロプロテイナーゼ−１３のアロステリックアルキン阻害薬とセレコキシブまたはバルデコキシブとの組合せ
WO2004014869A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
CA2492019A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Isoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
CA2494014A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
WO2004014908A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
DE60313350T2 (de) 2002-08-13 2008-01-03 Warner-Lambert Company Llc Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
MXPA05001786A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz.
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2004014923A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
CA2497658A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
AU2003250482A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
PT1560815E (pt) * 2002-11-02 2008-04-07 Sanofi Aventis Deutschland Novas diamidas do ácido pirimidino-4,6-dicarboxílico para a inibição selectiva de colagenases
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
MXPA06003951A (es) 2003-10-07 2006-06-27 Renovis Inc Derivados de amida como ligandos del canal de ion y composiciones farmaceuticas y sus metodos de uso.
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
CA2554437C (en) 2004-01-28 2011-06-21 Mitsui Chemicals, Inc. Amide derivatives, process for preparation thereof and use thereof as insecticide
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
WO2008002671A2 (en) * 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
WO2008112164A2 (en) 2007-03-08 2008-09-18 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
EP2337563B1 (en) * 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
JP5657201B2 (ja) * 2008-09-30 2015-01-21 サンメディカル株式会社 酵素阻害作用または酵素阻害作用と抗菌作用とを有する歯科用組成物
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
AR076177A1 (es) * 2009-04-01 2011-05-26 Colgate Palmolive Co MÉTODO PARA IDENTIFICAR UN COMPUESTO uTIL PARA TRATAR UNA ENFERMEDAD O CONDICIoN DE LA CAVIDAD ORAL
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
EP3464242A1 (en) * 2016-05-24 2019-04-10 Glaxosmithkline Intellectual Property (No. 2) Limited Pyridine dicarboxamide derivatives as bromodomain inhibitors
GB201703282D0 (en) * 2017-03-01 2017-04-12 Glaxosmithkline Intellectual Property (No 2) Ltd Compounds
GB201908453D0 (en) * 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1149356B (de) * 1955-03-24 1963-05-30 Bayer Ag Verfahren zur Herstellung von N-substituierten Thiosaeureamiden
US4971986A (en) * 1988-03-25 1990-11-20 Ciba-Geigy Corporation Arylhydrazones useful as SAMDC inhibitors
US5219847A (en) * 1989-06-12 1993-06-15 Shiseido Company, Ltd. Antipruritic composition
US5425289A (en) * 1993-10-21 1995-06-20 Snap-On Incorporated Bung tool
DE3924093A1 (de) * 1989-07-20 1991-02-07 Hoechst Ag N,n'-bis(alkoxy-alkyl)-pyridin-2,4-dicarbonsaeurediamide, verfahren zu deren herstellung sowie deren verwendung
DE3931432A1 (de) * 1989-09-21 1991-04-04 Hoechst Ag Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen
US5260323A (en) * 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
DE4020570A1 (de) * 1990-06-28 1992-01-02 Hoechst Ag 2,4- und 2,5-substituierte pyridin-n-oxide, verfahren zu deren herstellung sowie deren verwendung
PL172069B1 (pl) * 1991-05-22 1997-07-31 Pfizer Sposób wytwarzania nowych pochodnych podstawionej 3-aminochinuklidyny PL PL PL PL PL
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
EP0541042A1 (de) 1991-11-05 1993-05-12 Hoechst Aktiengesellschaft Pyridin-2,4- und 2,5-dicarbonsäureamide und deren Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
WO1998021207A1 (de) * 1996-11-12 1998-05-22 Byk Gulden Lomberg Chemische Fabrik Gmbh (2,3-dihydrobenzofuranyl)-thiazole als phosphodiesterasehemmer
CA2263886A1 (en) 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
JPH11199512A (ja) 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
UA59453C2 (uk) 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
US6300341B1 (en) * 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) * 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
IL145565A0 (en) * 1999-03-31 2002-06-30 Basf Ag Pyridine-2,3-dicarboxylic acid diamides
PA8498701A1 (es) 1999-08-12 2002-08-26 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
US6307490B1 (en) * 1999-09-30 2001-10-23 The Engineering Consortium, Inc. Digital to analog converter trim apparatus and method
US6934639B1 (en) 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
EP1138680A1 (en) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
US6916846B2 (en) * 2000-05-12 2005-07-12 Merck & Co. Inc. Coumermycin analogs as chemical dimerizers of chimeric proteins
SK4872003A3 (en) 2000-10-26 2004-08-03 Pfizer Prod Inc Metaloproteinase pyrimidine-2,4,6-trione inhibitors
CA2425283A1 (en) 2000-10-26 2002-05-02 Pfizer Products Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
WO2002064571A1 (en) 2001-02-14 2002-08-22 Warner-Lambert Company Llc Pyrimidine matrix metalloproteinase inhibitors
PA8539301A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
DOP2002000333A (es) * 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6933298B2 (en) * 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
DE10160357A1 (de) 2001-12-08 2003-06-18 Aventis Pharma Gmbh Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen
US20050004111A1 (en) * 2003-01-03 2005-01-06 Aventis Pharma Deutschland Gmbh Selective MMP-13 inhibitors

Also Published As

Publication number Publication date
CR7048A (es) 2004-04-22
MXPA03006204A (es) 2004-12-03
CZ20032143A3 (cs) 2003-11-12
CA2434982A1 (en) 2002-08-22
HN2002000025A (es) 2002-04-22
ES2283540T3 (es) 2007-11-01
KR20030075196A (ko) 2003-09-22
US20040209922A1 (en) 2004-10-21
PE20020995A1 (es) 2002-11-01
EE200300391A (et) 2003-12-15
NO20033570L (no) 2003-08-12
DE60219286D1 (de) 2007-05-16
MA26989A1 (fr) 2004-12-20
IL156912A0 (en) 2004-02-08
ECSP034691A (es) 2003-08-29
ZA200306041B (en) 2004-11-05
DOP2002000332A (es) 2002-08-30
GT200200014A (es) 2002-11-15
EP1362033A1 (en) 2003-11-19
BG108089A (en) 2005-01-31
US6881743B2 (en) 2005-04-19
US20020161000A1 (en) 2002-10-31
BR0207863A (pt) 2004-04-27
AP2003002840A0 (en) 2003-09-30
PL365098A1 (en) 2004-12-27
PA8538201A1 (es) 2003-06-30
HUP0303152A2 (hu) 2003-12-29
JP4249981B2 (ja) 2009-04-08
JP2004529878A (ja) 2004-09-30
US7015237B2 (en) 2006-03-21
UY27167A1 (es) 2002-09-30
ATE358667T1 (de) 2007-04-15
TNSN02012A1 (fr) 2005-12-23
DE60219286T2 (de) 2008-01-03
IS6871A (is) 2003-07-10
EP1362033B1 (en) 2007-04-04
SK10022003A3 (sk) 2004-06-08
NO20033570D0 (no) 2003-08-12
WO2002064568A1 (en) 2002-08-22
CN1537101A (zh) 2004-10-13
OA12544A (en) 2006-06-05
AR035936A1 (es) 2004-07-28
EA200300763A1 (ru) 2004-02-26

Similar Documents

Publication Publication Date Title
HN2002000028A (es) Pirimidinas inhibidoras de metaloproteinasas
ATE465146T1 (de) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
ECSP045104A (es) Ligandos de los receptores de los cannabinoides
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
NO20021329L (no) Kinaseinhibitorer som terapeutiske midler
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
MA26812A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases
HRP20010573B1 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
EE200300001A (et) Perindopriili tert-butüülamiinsoola kristallilinealfa-vorm
ATE283253T1 (de) Substituierte aminopropoxyarylderivate als lxr agonisten
ATE346067T1 (de) Carbolinderivate
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
DK1643984T3 (da) Anvendelse af parthenolidderivater som antileukæmiske og cytotoksske midler
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
TR200001452T2 (tr) Bifenilamidin türevleri.
HRPK20040372B3 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
EA200300392A1 (ru) Производные пиперазина с мостиковой связью
DE60112960D1 (de) Kondensierte pyridoindolderivate
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
NO20023001D0 (no) Substituerte piperazinderivater som MTP inhibitorer
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII